Symbols

BRTX

Biorestorative·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 1

Bearish signal 1

High Gross Profit Margin

Significant Net Income Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BRTX

Biorestorative Therapies, Inc.

A clinical stage company that develops regenerative medicine products and therapies using cell and tissue protocols

Industry

Pharmaceutical

Established Date

06/13/1997

Listing Date

11/05/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.biorestorative.com

Security Type

Common stock

Office address

40 Marcus Drive, Suite 1, Melville, New York 11747

Business

Introduction

Biorestorative Therapies, Inc. was incorporated in Nevada on June 13, 1997. The company is currently working on a Disc/Spine program with a preliminary research therapeutic product called BRTX-100. In March 2022, a US patent was issued in the Disc/Spine Program. The company submitted an IND application to the U.S. Food and Drug Administration (FDA) for authorization to begin a Phase 2 clinical trial investigating the use of BRTX-100 for chronic low back pain caused by degenerative disc disease. The company has received such authorization from the FDA and has commenced such clinical trials.

Earnings Call

Q1/2025

Estimate EPS-0.32

Actual EPS-0.64

Estimate Revenue380.00K

Actual Revenue25.00K

BioRestorative Therapies' Q1 2025: Key Contradictions in Ufedrinol Trials and Financial Strategy Unveiled

May 20,2025 05:23·
Earnings Decrypt

Q2/2025

Estimate EPS-0.41

Actual EPS-0.3

Estimate Revenue340.00K

Actual Revenue303.00K

BioRestorative Therapies Q2 2025: Navigating Key Contradictions in Clinical Trials and Regulatory Pathways

Aug 12,2025 08:02·
Earnings Decrypt

Company Financials

EPS

BRTX has released its 2025 Q3 earnings. EPS was reported at -0.33, versus the expected -0.38, beating expectations. The chart below visualizes how BRTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BRTX has released its 2025 Q3 earnings report, with revenue of 11.80K, reflecting a YoY change of -94.95%, and net profit of -3.04M, showing a YoY change of -178.38%. The Sankey diagram below clearly presents BRTX's revenue sources and cost distribution.